2.Advances in leukemia inhibitors targeting PI3K/AKT/mTOR pathway.
Le WANG ; Yajing CHU ; Tao CHENG ; Weiping YUAN
Chinese Journal of Hematology 2015;36(10):888-893
3.mTOR and non-small cell lung cancer.
Liang WANG ; Shaofa XU ; Wentao YUE
Chinese Journal of Lung Cancer 2010;13(1):69-72
Animals
;
Carcinoma, Non-Small-Cell Lung
;
drug therapy
;
metabolism
;
Humans
;
Intracellular Signaling Peptides and Proteins
;
antagonists & inhibitors
;
metabolism
;
Lung Neoplasms
;
drug therapy
;
metabolism
;
Protein-Serine-Threonine Kinases
;
antagonists & inhibitors
;
metabolism
;
Signal Transduction
;
drug effects
;
Sirolimus
;
therapeutic use
;
TOR Serine-Threonine Kinases
4.Research progress of p70 ribosomal protein S6 kinase inhibitors.
Zhi-jun TU ; Gao-yun HU ; Qian-bin LI
Acta Pharmaceutica Sinica 2015;50(3):261-271
p70 ribosomal protein S6 kinase (p70S6K), an important member of AGC family, is a kind of multifunctional Ser/Thr kinases, which plays an important role in mTOR signaling cascade. The p70 ribosomal protein S6 kinase is closely associated with diverse cellular processes such as protein synthesis, mRNA processing, glucose homeostasis, cell growth and apoptosis. Recent studies have highlighted the important role of S6K in cancer, which arose interests of scientific researchers for the design and discovery of anti-cancer agents. Herein, the mechanisms of S6K and available inhibitors are reviewed.
Antineoplastic Agents
;
Humans
;
Protein Kinase Inhibitors
;
chemistry
;
Ribosomal Protein S6 Kinases, 70-kDa
;
antagonists & inhibitors
;
metabolism
;
Signal Transduction
;
TOR Serine-Threonine Kinases
5.Mammalian target of rapamycin inhibitors for the targeted therapy of non-small cell lung cancer.
Acta Academiae Medicinae Sinicae 2010;32(2):239-242
The mammalian target of rapamycin (mTOR), a master regulator of translation initiation, has recently emerged as an attractive therapeutic target for cancer therapy. It has been demonstrated that mTOR inhibitors activate several cell survival pathways including phosphatidyl inositol 3-kinase/serine or threonine-specific protein kinase Akt and mitogen-activated protein kinase or extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase while suppressing mTOR signaling in different types of cancer cell lines and human tumor samples and thus make the cancer cells acquire resistance to the mTOR-targeted therapy. However, these cancer cells may be more dependent on (or addicted to) these survival pathways after receiving the mTOR-targeted therapy. It can be assumed that the combination of mTOR inhibitor and the suppressor of these survival pathways might achieve greater efficacy in inhibiting the growth of cancer cells. In this article we discuss the results of many pre-clinical and clinical studies of mTOR targeted therapy, with an emphasis of its effect against the non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
;
drug therapy
;
metabolism
;
Humans
;
Lung Neoplasms
;
drug therapy
;
metabolism
;
Sirolimus
;
therapeutic use
;
TOR Serine-Threonine Kinases
;
antagonists & inhibitors
;
metabolism
6.Mammalian target of rapamycin inhibitor abrogates abnormal osteoclastogenesis in neurofibromatosis type 1.
Ning LIU ; Ning XU ; Li-hui WEI ; Guo-lin CHAI
Chinese Medical Journal 2013;126(1):101-107
BACKGROUNDNeurofibromatosis type 1 (NF1) is the most common genetic syndrome predisposing patients to various tumors due to dysregulation of the Ras signaling pathway. Recent research has shown NF1 patients also suffer a spectrum of bone pathologies. The pathogenesis of NF1 bone diseases is largely unknown. There is no current treatment. By Nf1 heterozygote (Nf1+/-) mice and Nf1 conditional knockout mice, we and other groups demonstrated abnormal osteoblast and osteoclast function due to dysregulation of Ras signaling. However, the specific downstream effector pathways linked to NF1 abnormal osteoblastogenesis and osteoclastogenesis have not been defined. In this study, we investigated the Ras downstream effector related with NF1 bone disease.
METHODSWe used Nf1+/+ and Nf1+/- mice as normal and NF1 models. Bone stromal cells extracted from Nf1+/+ and Nf1+/- mice were induced osteoclasts. The osteoclast cell was stained by tartrate resistant acid phosphatase staining. The osteoclast cell number was counted and the surface area of osteoclast cells was calculated under the microscope. The mRNA of mammalian target of rapamycin (mTOR) was determined by quantitative reverse-transcription-polymerase chain reaction. The presence of ribosomal protein S6 kinase was determined by Western blotting.
RESULTSCompared with Nf1+/+ mice, Nf1+/- mice had about 20% more of osteoclast cells. These osteoclast cells were larger in size with more nuclei. Hyperactive mTOR was detected in Nf1+/- osteoclast cells. Inhibition of mTOR signaling by rapamycin in Nf1+/- osteoclasts abrogated abnormalities in cellular size and number.
CONCLUSIONmTOR pathway inhibition may represent a viable therapy for NF1 bone diseases.
Animals ; Male ; Mice ; Neurofibromatosis 1 ; drug therapy ; Osteoclasts ; drug effects ; physiology ; Osteogenesis ; drug effects ; Sirolimus ; pharmacology ; TOR Serine-Threonine Kinases ; antagonists & inhibitors ; physiology
7.The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges.
Bianca CHEAIB ; Aurélie AUGUSTE ; Alexandra LEARY
Chinese Journal of Cancer 2015;34(1):4-16
The phosphatidylinositol 3 kinase (PI3K) pathway is frequently altered in cancer, including ovarian cancer (OC). Unfortunately, despite a sound biological rationale and encouraging activity in preclinical models, trials of first-generation inhibitors of mammalian target of rapamycin (mTOR) in OC have demonstrated negative results. The lack of patient selection as well as resistance to selective mTOR complex-1 (mTORC1) inhibitors could explain the disappointing results thus far. Nonetheless, a number of novel agents are being investigated, including dual mTORC1/mTORC2, Akt, and PI3K inhibitors. Although it is likely that inhibition of the PI3K/Akt/mTOR pathway may have little effect in unselected OC patients, certain histological types, such as clear cell or endometrioid OC with frequent phosphatidylinositol-4,5-biphosphate 3-kinase, catalytic subunit alpha (PIK3CA) and/or phosphatase and tensin homolog (PTEN) alterations, may be particularly suited to this approach. Given the complexity and redundancy of the PI3K signaling network, PI3K pathway inhibition may be most useful in combination with either chemotherapy or other targeted therapies, such as MEK inhibitors, anti-angiogenic therapy, and hormonal therapy, in appropriately selected OC patients. Here, we discuss the relevance of the PI3K pathway in OC and provide an up-to-date review of clinical trials of novel PI3K inhibitors alone or in combination with cytotoxics and novel therapies in OC. In addition, the challenges of drug resistance and predictive biomarkers are addressed.
Antineoplastic Combined Chemotherapy Protocols
;
therapeutic use
;
Drug Resistance, Neoplasm
;
Female
;
Humans
;
Ovarian Neoplasms
;
drug therapy
;
Phosphatidylinositol 3-Kinases
;
antagonists & inhibitors
;
physiology
;
Proto-Oncogene Proteins c-akt
;
antagonists & inhibitors
;
physiology
;
Signal Transduction
;
drug effects
;
TOR Serine-Threonine Kinases
;
antagonists & inhibitors
;
physiology
8.Impact of genetic alterations on mTOR-targeted cancer therapy.
Chinese Journal of Cancer 2013;32(5):270-274
Rapamycin and its derivatives (rapalogs), a group of allosteric inhibitors of mammalian target of rapamycin (mTOR), have been actively tested in a variety of cancer clinical trials, and some have been approved by the Food and Drug Administration for the treatment of certain types of cancers. However, the single agent activity of these compounds in many tumor types remains modest. The mTOR axis is regulated by multiple upstream signaling pathways. Because the genes (e.g., PIK3CA, KRAS, PTEN, and LKB1) that encode key components in these signaling pathways are frequently mutated in human cancers, a subset of cancer types may be addicted to a given mutation, leading to hyperactivation of the mTOR axis. Thus, efforts have been made to demonstrate the potential impact of genetic alterations on rapalog-based or mTOR-targeted cancer therapy. This review will primarily summarize research advances in this direction.
Antibiotics, Antineoplastic
;
therapeutic use
;
Cell Line, Tumor
;
Class I Phosphatidylinositol 3-Kinases
;
Humans
;
Mutation
;
Neoplasms
;
drug therapy
;
metabolism
;
PTEN Phosphohydrolase
;
genetics
;
metabolism
;
Phosphatidylinositol 3-Kinases
;
genetics
;
metabolism
;
Protein-Serine-Threonine Kinases
;
genetics
;
metabolism
;
Proto-Oncogene Proteins
;
genetics
;
metabolism
;
Proto-Oncogene Proteins p21(ras)
;
Signal Transduction
;
Sirolimus
;
analogs & derivatives
;
therapeutic use
;
TOR Serine-Threonine Kinases
;
antagonists & inhibitors
;
metabolism
;
ras Proteins
;
genetics
;
metabolism
9.Molecular mechanism of rhein on inhibiting autophagic protein expression in renal tubular epithelial cells via regulating mTOR signaling pathway activation.
Yue TU ; Wei SUN ; Liu-bao GU ; Yi-Gang WAN ; Hao HU ; Hong LIU
China Journal of Chinese Materia Medica 2014;39(21):4090-4095
OBJECTIVETo explore the effects and molecular mechanisms of rhein on reducing starvation-induced autophagic protein expression in renal tubular epithelial ( NRK-52E) cells.
METHODHank's balanced salt solution (HBSS) was used to induce NRK-52E cells to be in the state of starvation. After the intervention of HBSS for 0, 0.5,1, 2 and 6 hours, firstly, the protein expression of microtubule-associated protein 1 light chain 3(LC3 I/II), which is a key protein in autophagy, was detected. Secondly, the protein expressions of mammalian target of rapamycin (mTOR) and phosphorylated-mTOR Ser2448 (p-mTOR S2448) were examined. And then, after the co-treatment of rhein (5 mg x L(-1)) and HBSS (1 mL) without or with mTOR inhibitor, rapamycin (100 nmol x L(-1)), the protein expressions of LC3 I/II, mTOR and p-mTOR S2448 were tested, respectively.
RESULTHBSS could induce the up-regulation of LC3 II and the down-regulation of p-mTOR S2448 at protein expression level in NRK-52E cells. The co-treatment of rhein and HBSS could reversely regulate the protein expressions of LC3 II and p-mTOR S2448 in NRK-52E cells significantly. The co-treatment of rapamycin, rhein and HBSS could recover the level of LC3 II protein expression in HBSS-intervened NRK-52E cells.
CONCLUSIONHBSS induces autophagy in renal tubular epithelial cells by inhibiting mTOR signaling pathway activation. Rhein reduces the autophagic protein expression in renal tubular epithelial cells through regulating mTOR signaling pathway activation, which is the possible effects and molecular mechanisms.
Animals ; Anthraquinones ; pharmacology ; Autophagy ; drug effects ; Cells, Cultured ; Epithelial Cells ; drug effects ; metabolism ; Isotonic Solutions ; pharmacology ; Kidney Tubules ; drug effects ; metabolism ; Microtubule-Associated Proteins ; genetics ; Rats ; Signal Transduction ; drug effects ; TOR Serine-Threonine Kinases ; antagonists & inhibitors ; genetics ; physiology
10.Frontier of Epilepsy Research - mTOR signaling pathway.
Experimental & Molecular Medicine 2011;43(5):231-274
Studies of epilepsy have mainly focused on the membrane proteins that control neuronal excitability. Recently, attention has been shifting to intracellular proteins and their interactions, signaling cascades and feedback regulation as they relate to epilepsy. The mTOR (mammalian target of rapamycin) signal transduction pathway, especially, has been suggested to play an important role in this regard. These pathways are involved in major physiological processes as well as in numerous pathological conditions. Here, involvement of the mTOR pathway in epilepsy will be reviewed by presenting; an overview of the pathway, a brief description of key signaling molecules, a summary of independent reports and possible implications of abnormalities of those molecules in epilepsy, a discussion of the lack of experimental data, and questions raised for the understanding its epileptogenic mechanism.
Astrocytes/metabolism
;
Cell Death
;
Epilepsy/diet therapy/drug therapy/*metabolism/virology
;
Humans
;
Ketogenic Diet
;
Protein Binding/physiology
;
Protein Kinase Inhibitors/therapeutic use
;
Receptors, Cannabinoid/metabolism
;
Signal Transduction/*physiology
;
Synapses/metabolism
;
TOR Serine-Threonine Kinases/antagonists & inhibitors/*metabolism
;
Temporal Lobe/metabolism